Key result
In streptozotocin-diabetic rats, 40.1% of injected hIGFBP-3 appeared in the 140-kDa complex at 2 minutes compared to 52.9% in controls (P<0.05).
Absolute Event Rate: 40.1% vs 52.9%
p-value: p=< 0.05
The rapid in vivo formation of the 140-kDa IGFBP-3 complex indicates a much greater availability of IGFs to the circulation than previously estimated.
No takes yet. Share an insight, caveat, or question.
Diabetes alters IGFBP-3 complexing in rats; leaves open effects on human IGF bioavailability and cardiometabolic risk.
MOIRA S. LEWITT (1993) studied this question. human IGFBP-3 iv bolus vs. control rats was evaluated on Percentage of hIGFBP-3 appearing in a 140-kDa complex within 2 min of injection (p=< 0.05). In streptozotocin-diabetic rats, 40.1% of injected hIGFBP-3 appeared in the 140-kDa complex at 2 minutes compared to 52.9% in controls (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: